erdafitinib
Showing 1 - 19 of 19
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,
Not yet recruiting
- Recurrent Glioblastoma, IDH-Wildtype
- +2 more
- Biospecimen Collection
- +2 more
- (no location specified)
May 13, 2023
Healthy Trial in Merksem (Erdafitinib, Carbamazepine)
Completed
- Healthy
- Erdafitinib
- Carbamazepine
-
Merksem, BelgiumClinical Pharmacology Unit
Jul 14, 2022
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)
Active, not recruiting
- Neoplasm
- Erdafitinib
-
Beijing, China
- +5 more
Jan 31, 2023
Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)
Recruiting
- Bladder Cancer
- +2 more
- Erdafitinib
-
Basking Ridge, New Jersey
- +6 more
Aug 22, 2022
Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma Trial in Toronto (biological, procedure,
Recruiting
- Bladder Carcinoma
- +7 more
- Atezolizumab
- +5 more
-
Toronto, Ontario, CanadaUniversity Health Network Princess Margaret Cancer Center LAO
Nov 8, 2022
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter
Recruiting
- Locally Advanced Bladder Urothelial Carcinoma
- +18 more
- Enfortumab Vedotin
- Erdafitinib
-
Los Angeles, California
- +2 more
Jun 28, 2022
Hepatic Impairment Trial in Kiel, Munchen (Erdafitinib)
Terminated
- Hepatic Impairment
- Erdafitinib
-
Kiel, Germany
- +1 more
Mar 26, 2021
Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)
Unknown status
- Lung Cancer
- +4 more
- ERDAFITINIB
-
Gauting, Bavaria, Germany
- +10 more
Nov 11, 2020
Advanced Solid Tumor Trial in Worldwide (Erdafitinib)
Recruiting
- Advanced Solid Tumor
- Erdafitinib
-
Tucson, Arizona
- +199 more
Jan 27, 2023
Urinary Bladder Tumors Trial in Worldwide (Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C))
Recruiting
- Urinary Bladder Neoplasms
- Erdafitinib
- +2 more
-
Tucson, Arizona
- +178 more
Mar 24, 2022
Urothelial Cancer Trial in Worldwide (Erdafitinib, Vinflunine, Docetaxel)
Recruiting
- Urothelial Cancer
- Erdafitinib
- +4 more
-
Anchorage, Alaska
- +414 more
Jul 14, 2022
Cancer, Tumors, Tumor Trial in Netherlands (Panitumumab, Olaparib, Dabrafenib)
Recruiting
- Cancer
- +3 more
- Panitumumab
- +32 more
-
Amersfoort, Utrecht, Netherlands
- +34 more
Oct 26, 2021
Advanced Cancers and FGFR Genetic Alterations Trial (Erdafitinib)
Approved for marketing
- Advanced Cancers and FGFR Genetic Alterations
- Erdafitinib
- (no location specified)
May 9, 2019
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
Healthy Trial in Merksem (Erdafitinib, Fluconazole, Itraconazole)
Completed
- Healthy
- Erdafitinib
- +2 more
-
Merksem, BelgiumClinical Pharmacology Unit
Sep 20, 2017
Healthy Trial in Lincoln (Erdafitinib)
Completed
- Healthy
- Erdafitinib
-
Lincoln, NebraskaCelerion
Jun 22, 2017
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022